Skip to main content

Table 1 Epidemiological input data used in the model a

From: Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe

Gender

Cancer sites (ICD 10 code)

Expected number of new cases, irrespective of HPV status

HPV prevalence by site (%)

Expected number of new cases attributable to HPV

Prevalence of HPV 16/18 in HPV-positive cancers (%)

Expected number of new cancer cases attributable to HPV 16/18

Prevalence of HPV 6/11 in HPV-positive warts (%)

Expected number of new cancer cases attributable to HPV 6/11

Male

Head and neckb

67,354

 

14,098

 

12,707

  
 

Anus (C21)

2,162

84.2

1,821

87.1/6.2

1,699

  
 

Penis (C60)

3,178

46.7

1,484

60.2/13.4

1,091

  
 

Genital warts

380,961

    

85.5

325,722

Female

Cervical cancer

30,517

-

-

59.2/17.0

23,254

  
 

Vaginal

1,869

69.9

1,306

76.8/10.9

1,146

  
 

Vulvar

7,384

40.4

2,983

79.7/10.9

2,702

  
 

Anus (C21)

3,727

84.3

3,141

87.1/6.2

2,929

  
 

Head and neck

13,448

 

2,715

 

2,531

  
 

Genital warts

337,963

    

85.5

288,959

  1. HPV, human papillomavirus.
  2. aIn total 26 countries were considered in the analysis for incidence estimates, i.e. all European Union countries (except Greece, Hungary, Luxembourg, and Romania). Three countries outside the European Union were included (Iceland, Norway and Switzerland).
  3. bincludes several ICD 10 codes related sites (i.e., tongue, gum of the mouth, floor of the mouth, palate, tonsil, piriform sinus), hypopharynx and larynx sites.